Internal Medicine, Hematology & Oncology · Rockville Center, NY
NPI
1205817335
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2000 N Village Ave
Rockville Center, NY, 11570
Phone (516) 763-1962
Groups this clinician bills Medicare through
Medicare paid, 2024
$298K
2,558 services
Medicare patients, 2024
469
Average age 77
Drug cost, 2024
$3.0M
694 prescriptions
Company payments, 2025
$4,208
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammed F Ali was code 99233 (hospital e&m - subsequent), 1,286 times for 223 patients. In total Mohammed F Ali billed 2,558 services in 15 codes, and Medicare paid $298K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 1,286 | 223 | $108.29 | $139K |
| 99214 Office E&M - Established | Office | 908 | 227 | $110.76 | $101K |
| 99223 Hospital E&M - Initial | Facility | 204 | 179 | $155.53 | $32K |
| 99205 Office E&M - New | Office | 93 | 93 | $192.86 | $18K |
| 99215 Office E&M - Established | Office | 29 | 27 | $164.10 | $4,759 |
By year: 2022 $335K for 3,069 services; 2023 $269K for 2,319 services; 2024 $298K for 2,558 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohammed F Ali prescribed most often to Medicare patients was Anastrozole, with 196 prescriptions and refills. In total Mohammed F Ali wrote 694 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 196 | 514 | 69 | $4,159 |
| Tamoxifen Citrate Generic | 48 | 144 | 17 | $1,868 |
| Letrozole Generic | 33 | 92 | 15 | $736 |
| Exemestane Generic | 30 | 73 | Under 11 | $4,773 |
| Lynparza Olaparib | 30 | 30 | Under 11 | $465K |
| Kisqali Femara Co-Pack Ribociclib Succinate/Letrozole | 22 | 22 | Under 11 | $345K |
| Hydroxyurea Generic | 22 | 56 | Under 11 | $544 |
| Xtandi Enzalutamide | 18 | 18 | Under 11 | $275K |
| Imatinib Mesylate Generic | 16 | 18 | Under 11 | $2,075 |
| Imbruvica Ibrutinib | 16 | 16 | Under 11 | $253K |
| Dexamethasone Generic | 15 | 16 | Under 11 | $273 |
| Revlimid Lenalidomide | 14 | 14 | Under 11 | $238K |
| Lenalidomide Generic | 14 | 14 | Under 11 | $188K |
Brand drugs: - claims; generic drugs: 515 claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammed F Ali $4,208 ($4,208 in general payments such as food, travel and fees) from 21 companies. The largest payer was Bayer Healthcare Pharmaceuticals Inc. with $1,587.
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $1,587 |
| Novartis Pharmaceuticals Corporation NVS | 25 | $1,270 |
| Daiichi Sankyo Inc. 4568.T | 1 | $650 |
| Merck Sharp & Dohme LLC MRK | 4 | $102 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $74.66 |
| GlaxoSmithKline, LLC. GSK | 2 | $55 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $51.95 |
| Stemline Therapeutics Inc. | 2 | $48.66 |
| TerSera Therapeutics LLC | 2 | $48.35 |
| Sobi, Inc SOBI.ST | 2 | $44.31 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.